Piper Sandler on Aquestive Therapeutics (AQST): 'Encouraging Feedback On Anaphylm'

August 26, 2025 8:07 AM EDT Send to a Friend
Piper Sandler analyst David Amsellem reiterated an Overweight rating and $5.00 price target on Aquestive Therapeutics (NASDAQ: AQST).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login